Effect on premiums is smallBMJ 2007; 334 doi: https://doi.org/10.1136/bmj.39247.696238.3A (Published 21 June 2007) Cite this as: BMJ 2007;334:1288
- R Guy Thomas, honorary lecturer
Neither Holm nor Ashcroft addresses the quantitative question: how much difference would genetic information make to insurance prices?1 2 Would banning insurers from access to genetic tests raise prices by 0.01% or 1% or 100%?
The answer is that it probably makes very little difference indeed. Certainly all estimates of the difference to date, under a variety of approaches and assumptions, have been negligible by comparison with the variations in insurance prices which exist for many other reasons.
To the very minor extent that prices do rise as a result of restricting insurers' access to genetic tests, this may not be a bad thing. In a competitive market, the logical corollary of an increase in insurance prices is an equivalent increase in claim payouts.
Competing interests: None declared.